All In MedTech

FDA Clearance Tracker · P030017-S358

mySCS™ GO Therapy Controller App

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Apr 4, 2024 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Apr 4, 2024

Approved

Time to decision

463 days

Received Dec 28, 2022. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track

Device class

Class III

The decision

FDA number
P030017-S358
Device name
mySCS™ GO Therapy Controller App
Applicant location
Valencia, CA
Received
Dec 28, 2022
Decided
Apr 4, 2024
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Change Design/Components/Specifications/Material
Original approval
P030017

Device type

Device class
Class III

Every decision under product code LGW

FDA's approval statement

As written in FDA's record.

Approval for a mobile application referred to as the mySCSTM GO Therapy Controller App. The mySCSTM GO Therapy Controller App will be used on an off-the-shelf mobile phone and functions as an alternate to the current FreelinkTM Remote Control (RC) to control the WaveWriter Alpha IPG and External Trial Stimulator (ETS) Systems (P030017/S338).

Source documents

Other decisions for Boston Scientific Corp

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.